Page d'accueil  |  Aide  |  Effacer
Anglais  |  Français
 Rechercher  |  Catégories  |  Titres A-Z  |  Pays  |  Comparer pays  |  Index  
Etendre sommaire
Document complet
Dérouler chapitre
Préférences

fermer ce livreStandard Treatment Guidelines (STG) and The National Essential Drug List for Tanzania (NEDLIT) (WHO; 1997; 210 pages)
Afficher le documentFOREWORD
Afficher le documentACKNOWLEDGMENTS
Afficher le documentINTRODUCTION
fermer ce répertoireStandard Treatment Guidelines (STG)
ouvrir ce répertoire et afficher son contenu1. GASTROINTESTINAL CONDITIONS
ouvrir ce répertoire et afficher son contenu2. RESPIRATORY DISEASES
ouvrir ce répertoire et afficher son contenu3. OBSTETRIC AND GYNAECOLOGICAL CONDITIONS AND CONTRACEPTION
ouvrir ce répertoire et afficher son contenu4. CARDIOVASCULAR DISEASES
ouvrir ce répertoire et afficher son contenu5. MALARIA
ouvrir ce répertoire et afficher son contenu6. SKIN DISEASES
ouvrir ce répertoire et afficher son contenu7. SEXUALLY TRANSMITTED INFECTIONS / DISEASES (STD)
ouvrir ce répertoire et afficher son contenu8. DENTAL AND ORAL CONDITIONS
ouvrir ce répertoire et afficher son contenu9. GENITO-URINARY DISEASES: KIDNEY CONDITIONS
ouvrir ce répertoire et afficher son contenu10. EAR, NOSE AND THROAT CONDITIONS
ouvrir ce répertoire et afficher son contenu11. EYE CONDITIONS
ouvrir ce répertoire et afficher son contenu12. TUBERCULOSIS AND LEPROSY
ouvrir ce répertoire et afficher son contenu13. MUSCULOSKELETAL CONDITIONS AND JOINT DISEASES
ouvrir ce répertoire et afficher son contenu14. METABOLIC AND ENDOCRINE SYSTEM CONDITIONS
ouvrir ce répertoire et afficher son contenu15. CENTRAL NERVOUS SYSTEM DISEASE CONDITIONS
ouvrir ce répertoire et afficher son contenu16. OTHER DISEASE CONDITIONS
ouvrir ce répertoire et afficher son contenu17. VIRAL INFECTIONS
ouvrir ce répertoire et afficher son contenu18. ALLERGIC REACTIONS
fermer ce répertoire19. NUTRITIONAL AND HAEMATOLOGIC CONDITIONS
fermer ce répertoireHAEMATOLOGICAL DISEASE CONDITIONS
Afficher le document19.1 Anaemia
Afficher le document19.2 Sickle Cell Anaemia
Afficher le document19.3 Q6PD deficiency
ouvrir ce répertoire et afficher son contenu19.4 Bleeding Disorders
Afficher le document19.5 Von Willebrand Disease (VWD)
Afficher le document19.6 Acquired Bleeding Disorders/Platelet Disorders
Afficher le document19.7 Haemorrhagic Disease of the Newborn
Afficher le document19.8 Anticoagulation
ouvrir ce répertoire et afficher son contenuNUTRITIONAL DISEASE CONDITIONS
ouvrir ce répertoire et afficher son contenu20. MALIGNANT DISEASE CONDITIONS
ouvrir ce répertoire et afficher son contenu21. INJURIES AND TRAUMA
Afficher le document22. FOREIGN BODIES
Afficher le document23. PAIN
Afficher le document24. POISONING
Afficher le document25. NORMAL LABORATORY VALUES
ouvrir ce répertoire et afficher son contenuNATIONAL ESSENTIAL DRUG LIST
Afficher le documentABBREVIATIONS AND SYMBOLS
 
19.8 Anticoagulation

Duration of treatment.

• Deep vein thrombosis (DVT): 6 - 8 weeks

Except in pregnancy, or if there is another reason for prolonged treatment.

• Pulmonary embolism (PE): 3 months

• Atrial fibrillation: life long treatment.

• Heart valve prostheses: life long treatment.


Heparin Treatment

Prophylaxis against DVT

following surgery and immobility e.g cardiac failure:

Heparin (SC) 5000 units every 8 hours until ambulant.


Treatment of DVT/PE

Heparin (IV) 10000 units every 6 hours.

Monitor APTT - aim for 2-3 times control.
Continue until warfarin is effective, usually 3-5 days.


If facilities for monitoring APTT and INR are not available, DVT, may be treated with:

Heparin (SC) 10000 units twice daily for 3 - 4 weeks.


DVT in pregnancy

Continue throughout pregnancy, aiming for APTT 2-3 times normal:

Heparin (SC) 10000 units twice daily;

OR


Warfarin after first trimester (12 weeks) keeping INR in the range 2-3. At 32-34 weeks stop Warfarin and change to Heparin as above.


CAUTION Warfarin may harm the foetus and should not be used under 12 weeks. Monitor closely whichever method is used. Specialist supervision is recommended.

Heparin Overdosage

If bleeding occurs, stop heparin and give:

Protamine sulphate (slow IV) 1 mg neutralises 100 units of Heparin. Maximum dose 50 mg (in excess protamine is also an anticoagulant).


Oral Anticoagulation

Warfarin (O) loading dose 10 mg once daily for 2 days. Check INR on 3rd day and dose accordingly. The drug should be taken at the same time each day.


Therapeutic Range for Warfarin use

DVT/PE: INR 2-3, heart valve prosthesis: INR 3-4.5.

There is great individual variation in dose (average daily dose 3-9 mg). Monitor INR regularly, initially daily/ alternate days then increase interval gradually to a maximum of 8 weeks. Reduce loading dose in elderly and in patients with renal/ hepatic impairment.

Drugs Interacting with Warfarin

CAUTION Drug interactions are common and can be dangerous

Below are a few examples:

Warfarin Inhibition

Warfarin Potentiation

Barbiturates

Alcohol

Oral contraceptives

Chloramphenicol

Griseofulvin

Cimetidine

Rifampicin

Erythromycin

Carbamazepine

Co-trimoxazole

Vitamin K

Acetylsalicylic acid

Warfarin Overdosage:

If INR 4.5-7 without haemorrhage - withhold Warfarin for 1-2 days then review.

If INR > 7 without haemorrhage - withhold Warfarin and check INR daily.

Consider giving:

Vitamin K (slow IV) 0.5-1 mg injection (not IM).

If INR > 4.5 with haemorrhage, give:

Fresh frozen plasma (FFP) 2-4 bags, then check INR and repeat infusion if bleeding continues.

Plus


Vitamin K (slow IV) 0.5 - 1 mg (higher doses Vitamin K will prevent adequate anticoagulation for up to 2 weeks).


Streptokinase Treatment

Life Threatening Pulmonary Embolism / Arterial Embolism

Streptokinase (IV) loading dose of 250000 units over 30 minutes, then 100000 units every hour for 24-72 hours

CAUTION allergic reactions may occur - before infusion give: hydrocortisone (IV) 100 mg.

vers la section précédentevers la section suivante

S'il vous plaît envoyez vos commentaires
Abréviations
Anglais  |  Français